Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- Sales of DPP-4 Inhibitors on Track to Reach ¥100 Bil. this Fiscal Year
January 16, 2012
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 16, 2012
- No Clear Road to Distribution Reform; New Drug Premium Hurting Wholesalers’ Business
January 16, 2012
- Research Oriented-companies Shake Up Generics Market with Established Products
January 16, 2012
- Taiyo to Be Core of Teva’s Operations in Japan
January 16, 2012
- Nichi-Iko Will Soon Decide on Independent or Joint PI Trial for Remicade Biosimilar: President Tamura
January 16, 2012
- Otsuka to Focus on CNS Field, Ending Collaboration in Immunology, Inflammation with UCB
January 16, 2012
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 15, 2012
- Nichi-Iko Posts Record-High Sales, Profits in FY2011
January 13, 2012
- Pfizer to Strengthen Role of Manufacturing Division by Spin-Off, Utilizing Its Formulation Technology
January 13, 2012
- Hisamitsu: Sales Up 1.2% Due to Favorable Performance of Overseas Subsidiaries
January 13, 2012
- Major Dispensing Pharmacies, Intermediary Companies Aggressively Seek M&A
January 12, 2012
- Survey Shows Astellas Website Most Frequently Accessed by Doctors
January 12, 2012
- Barclays Capital Report Mentions Tivozanib, Raises Astellas Pharma’s Target Stock Price
January 12, 2012
- Interprotein, Takeda Sign Collaboration Agreement on Molecular Design for PPI Modulators
January 12, 2012
- Sales of Ethical Drugs Up 5.2% in November: Crecon Report
January 12, 2012
- Administration of OTSA101 Started in Trial for Synovial Sarcoma: OncoTherapy
January 12, 2012
- Dispensing Point Services Should Continue: Mr Arai of Sugi HD
January 12, 2012
- Current Pollinosis Treatments Least Effective at Relieving Nasal Congestion: MSD
January 12, 2012
- Kyowa Kirin President Matsuda Aims for Global Presence in Biosimilar Business
January 11, 2012
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…